---
title: "Relay Therapeutics, Inc. (RLAY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RLAY.US.md"
symbol: "RLAY.US"
name: "Relay Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T02:03:58.021Z"
locales:
  - [en](https://longbridge.com/en/quote/RLAY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RLAY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RLAY.US.md)
---

# Relay Therapeutics, Inc. (RLAY.US)

## Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.relaytx.com](https://www.relaytx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.51)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 89 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 39.03% |  |
| Net Profit YoY | 18.20% |  |
| P/B Ratio | 3.61 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2318192596.50 |  |
| Revenue | 10676000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -40.01% | E |
| Profit Margin | -2554.37% | E |
| Gross Margin | -2252.10% | E |
| Revenue YoY | 39.03% | A |
| Net Profit YoY | 18.20% | B |
| Total Assets YoY | -12.48% | E |
| Net Assets YoY | -10.94% | D |
| Cash Flow Margin | 78.24% | C |
| OCF YoY | 39.03% | A |
| Turnover | 0.01 | E |
| Gearing Ratio | 8.21% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Relay Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "39.03%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "18.20%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.61",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2318192596.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "10676000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-40.01%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2554.37%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-2252.10%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "39.03%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "18.20%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.48%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-10.94%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "78.24%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "39.03%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.21%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.48 | 431/386 | - | - | - |
| PB | 3.60 | 281/386 | 3.09 | 1.90 | 0.87 |
| PS (TTM) | 216.60 | 275/386 | 169.69 | 128.00 | 78.14 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 85% |
| Overweight | 2 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.07 |
| Highest Target | 25.00 |
| Lowest Target | 18.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RLAY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RLAY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RLAY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RLAY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**